Pinc PeptideThe girly peptide research blog

Mazdutide · Dose evidence · updated 8 October 2026

Mazdutide dosage: what studies actually used

The short answer

China’s National Medical Products Administration (NMPA) approved mazdutide in 2025 for weight management and for type 2 diabetes, at 4 mg and 6 mg once a week123. As of 7 October 2026, no dose is approved in the US, where Lilly’s trials have tested up to 16 mg once a week456. This page reports those doses and is not dosing advice. Vials sold online are another matter: of the 29 mazdutide tests Finnrick listed from April to November 2025, 11 failed7.

Not dosing advice. This page reports doses that studies and approved labels used, with their sources. It does not recommend a dose, and we do not give mixing, injection or unit-conversion instructions. Gray-market vials often do not contain what their label says. How we report doses.

Every dose studied in people

StudyWhoPeopleDose and routeWhat happened
DREAMS-2 (Guo 2026), randomized trial Chinese adults with type 2 diabetes on oral diabetes drugs 731 4 or 6 mg once a week, versus dulaglutide 1.5 mg once a week
Injection under the skin · 28 weeks		 HbA1c fell 0.24 and 0.30 points more than on dulaglutide, and weight 3.78 and 5.76 percentage points more; digestive side effects were more common than on dulaglutide8.
GLORY-1 (Ji 2025), randomized trial Chinese adults with a BMI of 28 or more, or 24 to under 28 with a weight-related condition 610 4 or 6 mg once a week
Injection under the skin · 48 weeks		 Weight fell 11.00% and 14.01%, versus a 0.30% gain on placebo; 1.5% and 0.5% stopped because of side effects, versus 1.0%9.
GLORY-2 (Gao 2026), randomized trial Chinese adults with a BMI of 30 or more; 16.1% had type 2 diabetes 461 9 mg once a week
Injection under the skin · 60 weeks		 Weight fell 16.65%, versus 1.50% on placebo; vomiting affected 53.1% versus 1.3%, and 2.9% versus none stopped because of side effects10.
DREAMS-3 (Innovent press release 2025), randomized trial Chinese adults with obesity who had had type 2 diabetes for under 10 years 349 6 mg once a week, versus semaglutide 1 mg once a week
Injection under the skin · 32 weeks		 HbA1c below 7.0% together with at least 10% weight loss was reached by 48.0% versus 21.0% on semaglutide; weight fell 10.29% versus 6.00%11.
DREAMS-1 (Zhu 2026), randomized trial Chinese adults with type 2 diabetes not controlled by diet and exercise 320 4 or 6 mg once a week
Injection under the skin · 24 weeks, then a 24-week extension on mazdutide		 HbA1c fell 1.57 and 2.15 points, versus 0.14 on placebo; weight fell 5.61% and 7.81%, versus 1.26%12.
US phase 2 trial (Hsia 2026), randomized trial US adults with obesity or overweight, without type 2 diabetes 179 3 mg rising to 6 mg at week 32, 10 mg or 16 mg once a week
Injection under the skin · 48 weeks		 At 32 weeks, weight fell 7.3%, 15.6% and 18.1%, versus 0.9% on placebo, in an analysis that assumes everyone stayed on treatment; 20% stopped 16 mg because of side effects, mainly digestive ones5.
Phase 1b trial in type 2 diabetes (Jiang 2022), randomized trial Chinese adults with type 2 diabetes 42 3.0, 4.5 or 6.0 mg once a week, versus placebo or dulaglutide 1.5 mg
Injection under the skin · 12 weeks		 HbA1c and blood sugar fell in all three dose groups; the most common side effects on mazdutide were diarrhea (29.2%), decreased appetite (25.0%) and nausea (16.7%)13.
Phase 1b trial (Ji 2021), randomized trial Chinese adults with overweight or obesity 36 Up to 3.0, 4.5 or 6.0 mg once a week, in 4-week steps
Injection under the skin · 12 weeks, then 8 weeks of follow-up		 Weight fell 4.81%, 6.40% and 6.05% by week 12, versus a 0.60% gain on placebo; no one stopped treatment for safety reasons, and there were no serious side effects14.
US phase 1 trial (Bhattachar 2025), randomized trial US adults with overweight or obesity, without diabetes 32 16 mg once a week, reached by two different step-up plans
Injection under the skin · 20 weeks		 Weight fell 20.0% and 21.0% with the two plans, versus 0.1% on placebo; pulse rose by at least 10 beats a minute at two visits in a row in 91.7% versus 37.5%6.

Studies, animals and users: kept apart

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

In human studies

No dose is approved in the US. In China, the approved doses are 4 mg and 6 mg once weekly3, and a 9 mg dose was under review as of 25 August 202615. Trials used 4 mg or 6 mg weekly for 48 weeks in obesity9 and for 24 or 28 weeks in type 2 diabetes812, and 9 mg weekly for 60 weeks in obesity10, all injected under the skin. Lilly’s US trials tested weekly doses of up to 16 mg56.

In animal studies

Not summarized. Mazdutide has been tested directly in large human trials, so this entry does not rely on animal doses.

What users report

No community dosing page was cited for this compound.

Half-life and how it is taken

Half-life
About 6 to 17 days14Range in a 12-week study in 36 Chinese adults with overweight or obesity, at doses up to 6 mg weekly (150.9 to 403.5 hours). A 12-week study in type 2 diabetes reported 6.1 to 28.1 days13.
Routes
  • Subcutaneous injection once weekly (approved in China; the only route in the human studies we found)
  • No human data found for any other route

The approved doses in China

China’s NMPA approved mazdutide in June 2025 for long-term weight management in adults with an initial “BMI ≥ 28 kg/m² (obesity); or BMI ≥ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition”, and in September 2025 for blood-sugar control in adults with type 2 diabetes1211. Innovent, Lilly’s partner for mazdutide in China, lists both approvals at 4 mg and 6 mg3. Macau’s drug regulator (ISAF) approved it for the same uses in October 2025 and January 20263.

Innovent describes its dose range as “2mg-4mg-6mg” for the broad overweight and obese population and “3 mg-6mg-9mg” for people with severe obesity16. We did not review the Chinese prescribing information, so this page does not give the length of each step.

The 9 mg dose is not yet approved15. In November 2025, the NMPA’s Center for Drug Evaluation accepted Innovent’s application for 9 mg in adults with moderate to severe obesity, based on GLORY-2, and on 25 August 2026 Innovent said it was still under review1516.

How trials raised the dose

Every trial raised the dose in steps, and the plans differed5614:

  • Phase 1b in China: three 4-week steps, such as 2.0, 4.0 and then 6.0 mg in the 6.0 mg group14.
  • US phase 2: people in the 3 to 6 mg group stayed on 3 mg from week 4 to week 32 before moving up to 6 mg5.
  • US phase 1: two different step-up plans reached the same 16 mg target dose6.
  • DREAMS-3: after 32 weeks, people on mazdutide continued for 24 more weeks at different doses, depending on whether they had reached the weight-loss target11.

What the higher doses add, and what they cost

In GLORY-1, weight fell 14.01% on 6 mg and 11.00% on 4 mg at 48 weeks, and few people stopped because of side effects on either dose (0.5% and 1.5%)9. On 9 mg in GLORY-2, vomiting affected 53.1%, nausea 46.9% and diarrhea 39.4% of people, versus 1.3%, 3.2% and 6.5% on placebo10. In the US phase 2 trial, 20% of people on 16 mg stopped because of side effects, mainly digestive ones5.

Why gray-market vials make doses unreliable

FDA says companies have illegally sold unapproved GLP-1 drugs, including mazdutide, falsely labeled “for research purposes”, directly to consumers18. As of 7 October 2026, FDA’s warning-letter database listed four letters naming mazdutide, dated from 10 December 2024 to 24 August 2026192021.

Finnrick, an independent testing service, listed 29 mazdutide tests dated 25 April to 25 November 2025: 18 passed and 11 failed, as displayed on 7 October 20267. Its pass mark allows the measured dose to differ from the label by up to 35%7.

Questions people ask

How much mazdutide should I take?

No dose is approved in the US4. In China, where mazdutide is approved, the doses are 4 mg and 6 mg once a week, and Lilly’s US trials tested up to 16 mg a week35. Ask your prescriber about approved options.

What doses of mazdutide are approved in China?

4 mg and 6 mg once a week3. The approvals cover long-term weight management in adults with obesity, or with overweight and at least one weight-related condition, and blood-sugar control in adults with type 2 diabetes12.

What is the highest dose of mazdutide tested?

Among the trials on this page, 16 mg once a week, in Lilly’s US phase 1 and phase 2 trials56. In the phase 2 trial, 20% of people on 16 mg stopped because of side effects5.

Is mazdutide 9 mg approved?

Not as of 25 August 2026, the latest update found, when Innovent said its application for the 9 mg dose for adult weight management was still under review in China15. In GLORY-2, the trial behind the application, 9 mg once a week cut weight by 16.65% at 60 weeks, versus 1.50% on placebo1016.

Go deeper

Sources

  1. 1Voluntary Announcement: First Dual GCG/GLP-1 Receptor Agonist Mazdutide Received Approval by the National Medical Products Administration for Chronic Weight Management Innovent Biologics, Inc. (HKEXnews), 27 Jun 2025. www1.hkexnews.hk
  2. 2Voluntary Announcement: Mazdutide Received Approval from China’s National Medical Products Administration for Glycemic Control in Adults with Type 2 Diabetes Innovent Biologics, Inc. (HKEXnews), 19 Sep 2025. www1.hkexnews.hk
  3. 3Annual Report 2025 Innovent Biologics, Inc. (HKEXnews), 28 Apr 2026. www1.hkexnews.hk
  4. 4Drugs@FDA via openFDA: search for active ingredient mazdutide (no matches) U.S. Food and Drug Administration (openFDA), 6 Oct 2026. api.fda.gov · data query
  5. 5Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial The Lancet Diabetes & Endocrinology, 21 Aug 2026. pubmed.ncbi.nlm.nih.gov
  6. 6Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial Diabetes, Obesity and Metabolism, Nov 2025. pubmed.ncbi.nlm.nih.gov
  7. 7Mazdutide Safety Testing Results & Vendor Ratings Finnrick, accessed 7 Oct 2026. finnrick.com
  8. 8Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes Nature, Apr 2026. pubmed.ncbi.nlm.nih.gov
  9. 9Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight New England Journal of Medicine, 12 Jun 2025. pubmed.ncbi.nlm.nih.gov
  10. 10Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial JAMA, 4 Aug 2026. pubmed.ncbi.nlm.nih.gov
  11. 11Innovent’s Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3 Innovent Biologics (PR Newswire), 26 Oct 2025. prnewswire.com
  12. 12Mazdutide versus placebo in Chinese adults with type 2 diabetes Nature, Apr 2026. pubmed.ncbi.nlm.nih.gov
  13. 13A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes Nature Communications, 24 Jun 2022. pubmed.ncbi.nlm.nih.gov
  14. 14IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study EClinicalMedicine, Sep 2021. pubmed.ncbi.nlm.nih.gov
  15. 15Interim Results Announcement for the Six Months Ended 30 June 2026 Innovent Biologics, Inc. (HKEXnews), 25 Aug 2026. www1.hkexnews.hk
  16. 16Mazdutide 9mg Supplementary Application Accepted for Review by China’s NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population Innovent Biologics (PR Newswire), 25 Nov 2025. prnewswire.com
  17. 17Survodutide Once Weekly for the Treatment of Adults with Obesity New England Journal of Medicine, 20 Aug 2026. pubmed.ncbi.nlm.nih.gov
  18. 18FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss U.S. Food and Drug Administration, 1 Oct 2026. fda.gov
  19. 19Warning Letters (database search for mazdutide) U.S. Food and Drug Administration, accessed 7 Oct 2026. fda.gov
  20. 20Warning letter to Summit Research Peptides (MARCS-CMS 695607) U.S. Food and Drug Administration, 10 Dec 2024. fda.gov
  21. 21Warning letter to NuScience Peptides LLC (MARCS-CMS 733652) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov

Not medical advice. Talk to a licensed clinician before using any drug. Report an error.